Javascript must be enabled to continue!
Prognostic Significance of Free Psa/ Total Psa Ratio In Predicting Bone Metastases In Patients With Prostate Cancer
View through CrossRef
Abstract
Background
In this study, we aimed to investigate the prognostic value of free prostate specific antigen/total prostate specific antigen (free PSA/ total PSA) ratio in prediciton of bone metastases in patient with prostate cancer.
Methods
In total 175 patients with prostate cancer who underwent whole-body bone scintigraphy were included in the study. All selected scintigraphic studies were reprocessed. Free PSA/total PSA ratio, alkaline phosphatase(ALP) values and Gleason scores of patients were recorded.
Results
The results of our study shows that a moderate correlation between free PSA and ALP values with bone metastases lesion number. In addition, we detected a weak correlation between total PSA value, free PSA/ total PSA ratio and Gleason score with the number of bone metastases lesions in patients with prostate cancer. To predict bone metastases in prostat cancer, only ALP variable was statistically significant and had a high diagnostic value (AUC = 0.907, p = 0.004). ALP cut off value was 76.50 IU/L, with %80 sensitivity and %82.1 specificity. Additionally according to our results free PSA values, total PSA values, free PSA/total PSA ratio and Gleason score values was not considered as a reliable parameter in prostate cancer cases following bone metastasis development.
Conclusion
According to the results of our study; the free PSA, total PSA, free PSA/total PSA ratio and Gleason score values was not considered as a reliable parameter in the prostate cancer cases follow-up for bone metastasis development. In addition to ALP can predict bone metastases with 80% sensitivity and 82.1% specificity at 76.50 cut off value.
Springer Science and Business Media LLC
Title: Prognostic Significance of Free Psa/ Total Psa Ratio In Predicting Bone Metastases In Patients With Prostate Cancer
Description:
Abstract
Background
In this study, we aimed to investigate the prognostic value of free prostate specific antigen/total prostate specific antigen (free PSA/ total PSA) ratio in prediciton of bone metastases in patient with prostate cancer.
Methods
In total 175 patients with prostate cancer who underwent whole-body bone scintigraphy were included in the study.
All selected scintigraphic studies were reprocessed.
Free PSA/total PSA ratio, alkaline phosphatase(ALP) values and Gleason scores of patients were recorded.
Results
The results of our study shows that a moderate correlation between free PSA and ALP values with bone metastases lesion number.
In addition, we detected a weak correlation between total PSA value, free PSA/ total PSA ratio and Gleason score with the number of bone metastases lesions in patients with prostate cancer.
To predict bone metastases in prostat cancer, only ALP variable was statistically significant and had a high diagnostic value (AUC = 0.
907, p = 0.
004).
ALP cut off value was 76.
50 IU/L, with %80 sensitivity and %82.
1 specificity.
Additionally according to our results free PSA values, total PSA values, free PSA/total PSA ratio and Gleason score values was not considered as a reliable parameter in prostate cancer cases following bone metastasis development.
Conclusion
According to the results of our study; the free PSA, total PSA, free PSA/total PSA ratio and Gleason score values was not considered as a reliable parameter in the prostate cancer cases follow-up for bone metastasis development.
In addition to ALP can predict bone metastases with 80% sensitivity and 82.
1% specificity at 76.
50 cut off value.
Related Results
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract
Background: Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide. It is the third most common cancer in men in Algeri...
P107 Gastrointestinal symptoms in US patients with moderate-severe psoriasis and psoriatic arthritis
P107 Gastrointestinal symptoms in US patients with moderate-severe psoriasis and psoriatic arthritis
BACKGROUND:
In patients with psoriasis (PsO), increasing severity and the presence of psoriatic arthritis (PsA) elevate the risk of developing inflammatory bowel diseas...
Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume
Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume
AbstractBackgroundThe early diagnosis of prostate cancer (PCa) is mainly based on prostate‐specific antigen (PSA) blood levels and digital rectal examination. However, this approac...
Analysis of the spatial distribution and clinical features of prostate cancer in transperineal prostate biopsy
Analysis of the spatial distribution and clinical features of prostate cancer in transperineal prostate biopsy
Abstract
Background Recently, most studies on the spatial distribution of the prostate cancer are based on the samples confirmed by transrectal prostate biopsy (TRBx), whic...
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract
The human olfactomedin 4 gene (OLFM4) encodes an olfactomedin-related glycoprotein, which our group first cloned and characterized in myeloid cells and mapp...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
PSA Nadir and Time to PSA Nadir Following Androgen Deprivation Therapy are the Predictors for Castration-Resistant Prostate Cancer in Patients with Metastatic Prostate Cancer
PSA Nadir and Time to PSA Nadir Following Androgen Deprivation Therapy are the Predictors for Castration-Resistant Prostate Cancer in Patients with Metastatic Prostate Cancer
Purpose: To evaluate the influence of nadir prostate-specific antigen (PSA) level and time to PSA nadir following androgen deprivation therapy (ADT)on disease progression of castra...

